Suppr超能文献

间质干细胞诱导产生的肝细胞样细胞的临床应用:文献综述。

Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review.

机构信息

Hepatx Corporation, Palo Alto, CA 94304, USA.

Department of Pathology, School of Medicine, University of California, San Francisco, CA 94143, USA.

出版信息

Cells. 2022 Jun 22;11(13):1998. doi: 10.3390/cells11131998.

Abstract

Liver disease is a leading cause of mortality worldwide, resulting in 1.3 million deaths annually. The vast majority of liver disease is caused by metabolic disease (i.e., NASH) and alcohol-induced hepatitis, and to a lesser extent by acute and chronic viral infection. Furthermore, multiple insults to the liver is becoming common due to the prevalence of metabolic and alcohol-related liver diseases. Despite this rising prevalence of liver disease, there are few treatment options: there are treatments for viral hepatitis C and there is vaccination for hepatitis B. Aside from the management of metabolic syndrome, no direct liver therapy has shown clinical efficacy for metabolic liver disease, there is very little for acute alcohol-induced liver disease, and liver transplantation remains the only effective treatment for late-stage liver disease. Traditional pharmacologic interventions have failed to appreciably impact the pathophysiology of alcohol-related liver disease or end-stage liver disease. The difficulties associated with developing liver-specific therapies result from three factors that are common to late-stage liver disease arising from any cause: hepatocyte injury, inflammation, and aberrant tissue healing. Hepatocyte injury results in tissue damage with inflammation, which sensitizes the liver to additional hepatocyte injury and stimulates hepatic stellate cells and aberrant tissue healing responses. In the setting of chronic liver insults, there is progressive scarring, the loss of hepatocyte function, and hemodynamic dysregulation. Regenerative strategies using hepatocyte-like cells that are manufactured from mesenchymal stromal cells may be able to correct this pathophysiology through multiple mechanisms of action. Preclinical studies support their effectiveness and recent clinical studies suggest that cell replacement therapy can be safe and effective in patients with liver disease for whom there is no other option.

摘要

肝脏疾病是全球范围内主要的致死原因之一,每年导致 130 万人死亡。绝大多数肝脏疾病是由代谢性疾病(即 NASH)和酒精性肝炎引起的,在较小程度上是由急性和慢性病毒感染引起的。此外,由于代谢和酒精相关肝病的普遍存在,对肝脏的多重损伤变得很常见。尽管肝脏疾病的患病率不断上升,但治疗选择却很少:丙型肝炎病毒有治疗方法,乙型肝炎有疫苗。除了代谢综合征的管理之外,没有直接针对代谢性肝病的肝脏治疗方法显示出临床疗效,急性酒精性肝病的治疗方法很少,肝移植仍然是晚期肝病的唯一有效治疗方法。传统的药物干预未能显著影响酒精性肝病或终末期肝病的病理生理学。由于三个因素,开发肝脏特异性疗法的困难很大,这三个因素在任何原因引起的晚期肝病中都很常见:肝细胞损伤、炎症和异常组织修复。肝细胞损伤导致组织损伤和炎症,使肝脏对额外的肝细胞损伤敏感,并刺激肝星状细胞和异常组织修复反应。在慢性肝损伤的情况下,会出现进行性瘢痕形成、肝细胞功能丧失和血液动力学失调。使用间充质基质细胞制造的肝样细胞的再生策略可能通过多种作用机制纠正这种病理生理学。临床前研究支持其有效性,最近的临床研究表明,对于没有其他选择的肝病患者,细胞替代疗法可能是安全有效的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验